Cite
HARVARD Citation
Maio, M. et al. (n.d.). Tremelimumab as second-line or third-line treatment in relapsed malignant mesothelioma (DETERMINE): a multicentre, international, randomised, double-blind, placebo-controlled phase 2b trial. Lancet oncology. 18 (9), pp. 1261-1273. [Online].